News & Views
Licencing Agreement to Further Preclinical Disease Modelling
Jun 16 2019
Danish life sciences business Bioneer A/S, has been granted access to ERS Genomics’ CRISPR/Cas9 genome editing technology intellectual property, to generate a range of human cell based disease models.
The licensing agreement, will enable Hørsholm-based Bioneer to generate and commercialise CRISPR-edited cell based models, broadening its core capabilities and expanding on Bioneer's expertise in biomedical research support.
Eric Rhodes, CEO of ERS Genomics, said: “Bioneer has proven expertise in a broad array of biomedical fields. Adding CRISPR/Cas9 to their toolbox ensures they remain on the leading edge of technology. We are very pleased that Bioneer chose to expand on its service offering by licensing CRISPR/Cas9 technology through ERS Genomics."
“This cutting-edge technology will complement Bioneer’s competences in advanced preclinical disease modelling.” stated Lars H. Pedersen, CEO of Bioneer. Company CSO Christian Clausen added “Bioneer is working with both industry and academia to solve complex disease relevant questions by using advanced disease modelling. The CRISPR/Cas9 tools will enable clients and collaborators to precisely tailor their preclinical modelling strategies to their specific needs for predictive in vitro models.”
Financial details of the agreement were not disclosed.
Digital Edition
LMUK 49.7 Nov 2024
November 2024
News - Research & Events News - News & Views Articles - They’re burning the labs... Spotlight Features - Incubators, Freezers & Cooling Equipment - Pumps, Valves & Liquid Hand...
View all digital editions
Events
Nov 11 2024 Dusseldorf, Germany
Nov 12 2024 Cologne, Germany
Nov 12 2024 Tel Aviv, Israel
Nov 18 2024 Shanghai, China
Nov 20 2024 Karachi, Pakistan